Ipsen Company Description

Ipsen S.A. operates as a biopharmaceutical company worldwide.

The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.

The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases.

The company was founded in 1929 and is based in Boulogne-Billancourt, France.

Ipsen S.A.

Country	France
Founded	1929
Industry	Pharmaceutical Preparations
Employees	5,358
CEO	David Loew

Contact Details

Address: 65, quai Georges Gorse Boulogne-Billancourt, 92100 France
Phone	33 1 58 33 50 00
Website	ipsen.com

Stock Details

Ticker Symbol	I7G
Exchange	Frankfurt Stock Exchange
Fiscal Year	January - December
Reporting Currency	EUR
SIC Code	2834

Key Executives

Name	Position
David Loew	Chief Executive Officer
Aymeric Le Chatelier	Chief Financial Officer
Khalid Deojee	Head of Investor Relations